XML 64 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 11, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Sep. 30, 2015
USD ($)
Apr. 30, 2015
USD ($)
Sep. 30, 2013
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2017
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Revenue recognized                     $ 354,000   $ 1,000,000  
Deferred grant funding   $ 0       $ 0         2,620,985   2,620,985  
ApolloBio                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Deferred revenue   0       0         0   0  
Revenue recognized                         23,000,000  
MedImmune                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Deferred revenue   1,145,500       1,145,500         846,000   846,000  
Accounts receivable   1,693,530       1,693,530         1,092,530   1,092,530  
Revenue recognized                         882,000  
Collaborative Arrangement, Product | ApolloBio                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Territory expansion option period     3 years                      
Proceeds received in upfront payment         $ 19,400,000                  
Upfront payment received         23,000,000           23,000,000      
Advisory fees         960,000                  
Additional revenue to be achieved                         $ 20,000,000  
Royalty period                         10 years  
Period from effective date for termination                         1 year  
Number of days written notice defore termination                         90 days  
Collaborative Arrangement, Product | MedImmune                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Upfront payment received   $ 27,500,000           $ 27,500,000            
Anticipated development and regulatory event based payment receivable milestones                         $ 355,000,000  
Anticipated commercial event based payment receivable milestones                         345,000,000  
Number of additional products to be developed | product       2                    
Milestone payment, revenue recognized           $ 7,000,000                
Revenue under collaborative research and development arrangements                     1,400,000 $ 14,200,000 2,700,000 $ 14,500,000
Deferred revenue                     846,000   846,000  
Accounts receivable                     1,100,000   1,100,000  
Collaborative Arrangement, Product | Roche                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Full payment             $ 8,500,000              
Collaborative Arrangement, Product | Hoffman-La Roche                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Upfront payment received                   $ 10,000,000        
Revenue recognized                     0 2,100,000 0 6,100,000
Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Collaborative agreement, funding to be received $ 56,000,000                          
Collaborative agreement, period to receive funding for research and development 5 years                          
Funding received for research and development                     834,000   834,000  
Deferred grant funding                     2,400,000   2,400,000  
Collaborative Arrangement, Product | Defense Advanced Research Projects Agency (DARPA)                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Accounts receivable                     569,000   569,000  
Funding received for research and development                     496,000 $ 2,700,000 872,000 $ 7,800,000
Deferred grant funding                     130,000   130,000  
Base award                 $ 19,600,000          
Option award                 $ 24,600,000          
Total funding received for research and development                     $ 43,400,000   $ 43,400,000  
Foreign Tax Authority | Collaborative Arrangement, Product | ApolloBio                            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                            
Foreign corporate income taxes reducing upfront payment         2,200,000                  
Foreign non-corporate income taxes reducing upfront payment         $ 1,400,000